<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04221555</url>
  </required_header>
  <id_info>
    <org_study_id>AMC2001</org_study_id>
    <nct_id>NCT04221555</nct_id>
  </id_info>
  <brief_title>Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma</brief_title>
  <official_title>Neoadjuvant Durvalumab (MEDI4736) Plus Docetaxel, Oxaliplatin, S-1 (DOS) Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient (pMMR) Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neoadjuvant durvalumab (MEDI4736) plus docetaxel, oxaliplatin, S-1 (DOS) followed by surgery
      and adjuvant durvalumab plus S-1 chemotherapy in potentially resectable MMR proficient (pMMR)
      gastric or gastroesophageal junction (GEJ) adenocarcinoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Treatment for the main treatment group (pMMR tumor)

             1. Neoadjuvant treatment Durvalumab 1120 mg IV on day (D) 1, Docetaxel 50 mg/m2
                intravenously (IV) on D1, oxaliplatin 100 mg/m2 IV on D1, S-1 40 mg/m2 bid orally
                on D1-14, will be administered every three weeks for three cycles.

             2. Surgery

             3. Adjuvant treatment After 4-6 weeks from surgery, S-1 40 mg/m2 bid orally on D1-28
                plus durvalumab 1120 mg on D1 and D22 will be administered every 6 weeks for 12
                months as an adjuvant treatment.

        -  Treatment for the exploratory group (dMMR tumor)

             1. Neoadjuvant treatment Durvalumab 1500 mg IV and tremelimumab 75 mg IV on D1 will be
                administered every four weeks for three cycles.

             2. Surgery

             3. Adjuvant treatment After 4-6 weeks from surgery, durvalumab 1500 mg on D1 will be
                administered every 4 weeks for 12 months as an adjuvant treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 13, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic complete regression (pCR) rate</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease free survival (DFS)</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Resectable Gastric or Gastroesophageal Junction Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>the main treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pMMR tumor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>the exploratory group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dMMR tumor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel, Oxaliplatin, S-1 and Durvalumab</intervention_name>
    <description>Neoadjuvant treatment Durvalumab 1120 mg IV on day (D) 1, Docetaxel 50 mg/m2 intravenously (IV) on D1, oxaliplatin 100 mg/m2 IV on D1, S-1 40 mg/m2 bid orally on D1-14, will be administered every three weeks for three cycles.
Surgery
Adjuvant treatment After 4-6 weeks from surgery, S-1 40 mg/m2 bid orally on D1-28 plus durvalumab 1120 mg on D1 and D22 will be administered every 6 weeks for 12 months as an adjuvant treatment.</description>
    <arm_group_label>the main treatment group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab and Tremelimumab</intervention_name>
    <description>Neoadjuvant treatment Durvalumab 1500 mg IV and tremelimumab 75 mg IV on D1 will be administered every four weeks for three cycles.
Surgery
Adjuvant treatment After 4-6 weeks from surgery, durvalumab 1500 mg on D1 will be administered every 4 weeks for 12 months as an adjuvant treatment.</description>
    <arm_group_label>the exploratory group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Newly diagnosed pathologically proven potentially resectable gastric or GEJ
             adenocarcinoma

          2. Clinical stages of T3-4N0 or T2-4N+ according to the American Joint Committee on
             Cancer (AJCC) 8th edition by computed tomography (CT)

          3. Microsatellite-instability (MSI) status determined by immunohistochemical (IHC)
             staining

          4. No peritoneal seeding identified by laparoscopy if suspected by CT

          5. Capable of giving signed informed consent which includes compliance with the
             requirements and restrictions listed in the informed consent form (ICF) and in this
             protocol. Written informed consent and any locally required authorization obtained
             from the patient/legal representative prior to performing any protocol-related
             procedures, including screening evaluations

          6. Age &gt; 18 years at time of study entry

          7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          8. Life expectancy of &gt; 12 months

          9. Body weight &gt; 30kg

         10. No existing neuropathy

         11. Adequate normal organ and marrow function as defined below:

               -  Haemoglobin ≥9.0 g/dL

               -  Absolute neutrophil count (ANC) 1.5 (or 1.0) x (&gt; 1500 per mm3)

               -  Platelet count ≥100 (or 75) x 109/L (&gt;75,000 per mm3)

               -  Serum bilirubin ≤1.5 x institutional upper limit of normal (ULN)

               -  AST (SGOT)/ALT (SGPT) ≤2.5 x institutional ULN

               -  Measured creatinine clearance (CL) &gt; 40 mL/min or Calculated creatinine CL&gt;40
                  mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour
                  urine collection for determination of creatinine clearance:

         12. Evidence of post-menopausal status or negative urinary or serum pregnancy test for
             female pre-menopausal patients. Women will be considered post-menopausal if they have
             been amenorrheic for 12 months without an alternative medical cause.

         13. Patient is willing and able to comply with the protocol for the duration of the study
             including undergoing treatment and scheduled visits and examinations including follow
             up

        Exclusion Criteria:

          1. Participation in another clinical study with an investigational product during the
             last 2 weeks

          2. Concurrent enrollment in another clinical study, unless it is an observational
             (non-interventional) clinical study or during the follow-up period of an
             interventional study

          3. Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer
             treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g.,
             hormone replacementtherapy) is acceptable

          4. Major surgical procedure within 28 days prior to the first dose of durvalumab

          5. Distant metastasis including M1 lymph node

          6. Unable to take medication orally

          7. Gastric outlet obstruction and/or severe gastrointestinal bleeding

          8. Impaired bowel absorption, including any of the following:

               -  Bowel obstruction

               -  Chronic inflammatory bowel disease

               -  History of extended bowel resection

               -  Gastric dumping syndrome

          9. History of allogenic organ transplantation

         10. Active or prior documented autoimmune or inflammatory disorders (including
             inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with
             the exception of diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome,
             or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid
             arthritis, hypophysitis, uveitis, etc]). The following are exceptions to this
             criterion:

               -  Patients with vitiligo or alopecia

               -  Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on
                  hormone replacement

               -  Any chronic skin condition that does not require systemic therapy

               -  Patients without active disease in the last 5 years may be included but only
                  after consultation with the study physician

               -  Patients with celiac disease controlled by diet alone

         11. Uncontrolled intercurrent illness, including but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable
             angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic
             gastrointestinal conditions associated with diarrhea, or psychiatric illness/social
             situations that would limit compliance with study requirement, substantially increase
             risk of incurring adverse events (AEs) or compromise the ability of the patient to
             give written informed consent

         12. History of another primary malignancy except for

               -  Malignancy treated with curative intent and with no known active disease ≥ 5
                  years before the first dose of durvalumab and of low potential risk for
                  recurrence

               -  Adequately treated non-melanoma skin cancer or lentigo maligna without evidence
                  of disease

               -  Adequately treated carcinoma in situ without evidence of disease

         13. Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥470 ms
             calculated from 3 ECGs (within 15 minutes at 5 minutes apart)

         14. History of active primary immunodeficiency

         15. Active infection including tuberculosis (clinical evaluation that includes clinical
             history, physical examination and radiographic findings, and TB testing in line with
             local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result),
             hepatitis C, or human immunodeficiency virus (positive HIV 1/2 antibodies). Patients
             with a past or resolved HBV infection (defined as the presence of hepatitis B core
             antibody [anti-HBc] and absence of HBsAg) are eligible. Patients positive for
             hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative
             for HCV RNA.

         16. Current or prior use of immunosuppressive medication within 14 days before the first
             dose of durvalumab. The following are exceptions to this criterion:

               -  Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra
                  articular injection)

               -  Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of
                  prednisone or its equivalent

               -  Steroids as premedication for hypersensitivity reactions (e.g., CT scan
                  premedication)

         17. Receipt of live attenuated vaccine within 30 days prior to the first dose of
             durvalumab. Note: Patients, if enrolled, should not receive live vaccine whilst
             receiving durvalumab and up to 30 days after the last dose of durvalumab

         18. Female patients who are pregnant or breastfeeding or male or female patients of
             reproductive potential who are not willing to employ effective birth control from
             screening to 90 days after the last dose of durvalumab

         19. Known allergy or hypersensitivity to any of the study drugs or any of the study drug
             excipients

         20. Prior randomisation or treatment in a previous durvalumab or tremelimumab clinical
             study regardless of treatment arm assignment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoon-Koo Kang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>YoonKoo Yoon, MD, PhD</last_name>
    <phone>+82-2-3010-2043</phone>
    <email>ykkang@amc.seoul.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Min-Hee Ryu, MD, PhD</last_name>
    <phone>+82-2-3010-5935</phone>
    <email>miniryu@amc.seoul.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoon-Koo Kang, MD, PhD</last_name>
      <phone>82-2-3010-3230</phone>
      <email>ykkang@amc.seoul.kr</email>
    </contact>
    <contact_backup>
      <last_name>Min-Hee Ryu, MD, PhD</last_name>
      <phone>82-2-3010-5935</phone>
      <email>miniryu@amc.seoul.kr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 6, 2020</study_first_submitted>
  <study_first_submitted_qc>January 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2020</study_first_posted>
  <last_update_submitted>June 1, 2020</last_update_submitted>
  <last_update_submitted_qc>June 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Yoon-Koo Kang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

